Switch strategies | Pedro Cahn, MD, PhD

European HIV Clinical Forum 2018

Reduced drug regimens - What are the Data? | José Arribas, MD

European HIV Clinical Forum 2018

Resistance to Integrase Inhibitors - What Clinicians Need to Know | Roger Paredes, MD, PhD

European HIV Clinical Forum 2018

Remdesivir — What do the Clinical Trials Tell Us? - Daniel Kuritzkes, MD

COVID-19 Online Educational Program 2020

One pill a day?: Integration novel delivery systems into routine care | Terry Blaschke, MD

Global HIV Clinical Forum 2018

Designing e-health interventions for HIV care | Guido van den Berk, MD, PhD

Global HIV Clinical Forum 2018

Clinical case: Integrase Inhibitors in Africa | Julia Turner, MD

Global HIV Clinical Forum 2018

Implication of the resent Dolutegravir data | Rebecca Zash, MD

Global HIV Clinical Forum 2018

What is the Virological support for reduced drug regimens? | Daniel Kuritzkes, MD

Global HIV Clinical Forum 2018

State of the ART: Integrase Inhibitors (clinical overview) | Mauro Schechter, MD, PhD

Global HIV Clinical Forum 2018

Future perspective for delivery of antiretroviral drugs | David Back, PhD

Rio de Janeiro HIV Clinical Forum 2018

Simplified regimens: pros and cons | Pedro Cahn, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Clinical case presentation | Tânia Vergara, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Optimal use of INSTI’s in routine practice | Carlos Brites, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

SIERJ SESSION: Is early ART for everyone? | Mauro Schechter, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Clinical case presentation | Marcio de Figueiredo Fernandes, MD

Rio de Janeiro HIV Clinical Forum 2018

HIV prevention and the role of integrase inhibitors | Pep Coll, MD

Rio de Janeiro HIV Clinical Forum 2018

INSTIs in women and pregnancy | Sharon Walmsley, FRCPC, MD, MSC

Rio de Janeiro HIV Clinical Forum 2018

DDIs, INSTIs, TB and hepatitis | David Back, PhD

Rio de Janeiro HIV Clinical Forum 2018

Transmitted resistance to ARVs and its impact on initial therapy | Ricardo Diaz, MD

Rio de Janeiro HIV Clinical Forum 2018

Resistance to Integrase Inhibitors | Charles Boucher, MD, PhD

Rio de Janeiro HIV Clinical Forum 2018

Integrase Inhibitors in Women and Pediatrics | Alberto Chaparro-Sánchez, MD

Mexican HIV Clinical Forum 2018

Optimal use of Integrase Inhibitors in Routine Patient Care in Mexico | Luis Soto-Ramirez, MD

Mexican HIV Clinical Forum 2018

Clinical case presentation | Santiago Pérez Patrigeon, PhD

Mexican HIV Clinical Forum 2018